Frequently Asked Questions
Factors such as the rising prevalence of chronic conditions with multiple comorbidities are the major growth-driving factors.
Lantheus (U.S.), Bracco Imaging S.p.A. (Italy), General Electric (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), nanoPET Pharma GmbH (Germany), Trust Bio-sonics (Taiwan), FUJIFILM VisualSonics Inc. (Canada), Trivitron Healthcare (India) and Siemens (Germany) are the major companies operating in this market.
North America dominates the microbubble contrast media market due to an increase in the availability of advanced technologies, the presence of well-established healthcare facilities, and the demand for diagnostic procedures in this region.
Asia-Pacific is expected to dominate at the highest growth rate in the forecast period of 2022 to 2029 due to the rise in the research and development investment in the contrast agents in this region and the prevalence of chronic disease.
